In the TCGA data, we also find that the main target of the fusion is IGF2BP3, even though the breakpoints are different: whereas Panebianco et al. [34] reported that LOC389473 was a hotspot for breakpoints in their thyroid cancer cohort, none of the six IGF2BP3UIB in our cohort was located there. The gene discussed is IGF2BP3; the disease is thyroid gland carcinoma.